Focus on clozapine withdrawal- and misuse-related cases, as reported to the European Medicines Agency (EMA) pharmacovigilance database

Stephania Chiappini, Fabrizio Schifano, John Martin Corkery, Amira Guirguis

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)
64 Downloads (Pure)

Abstract

Background: Clozapine is of high clinical relevance for the management of both treatment-resistant schizophrenia and psychotic disturbances with concurrent drug misuse. Although the molecule presents with a range of well-known side-effects, its discontinuation/withdrawal syndrome has been only anecdotally described. Aims: the 2005–2018 European Medicines Agency (EMA) dataset of Adverse Drug Reactions (ADRs) was analyzed to identify and describe possible clozapine withdrawal-and misuse-/abuse-/dependence-related issues. Method: A descriptive analysis of clozapine-related ADRs was performed when available, data on ADRs’ outcome, dosage, and possible concomitant drug(s) were considered. Results: Out of 11,847 clozapine-related ADRs, some 599 (5.05%) were related to misuse/abuse/dependence/withdrawal issues, including 258 withdrawal-related (43.1%); 241 abuse-related (40.2%); and 80 intentional product misuse-related (13.3%) ADRs. A small number of overdose-and suicide-related ADRs were reported as well. Clozapine was typically (69.2%) identified alone, and most (84.7%) fatalities/high-dosage intake instances were reported in association with a history of substance abuse. Conclusions: Previous suggestions about the possibility of a clozapine discontinuation/withdrawal occurrence are here supported, but further studies are needed. However, the misuse/abuse cases here identified might be difficult to interpret, given the lack of studies highlighting the possible recreational use of clozapine. The high-dosage intake, fatal outcomes and clozapine/polydrug abuse issues reported here may, however, be a reason for concern.

Original languageEnglish
Article number105
Number of pages18
JournalBrain Sciences
Volume10
Issue number2
DOIs
Publication statusPublished - 16 Feb 2020

Keywords

  • Adverse drug reactions
  • Clozapine
  • Dependence
  • Misuse
  • Overdose
  • Withdrawal

Fingerprint

Dive into the research topics of 'Focus on clozapine withdrawal- and misuse-related cases, as reported to the European Medicines Agency (EMA) pharmacovigilance database'. Together they form a unique fingerprint.

Cite this